Downloads

Title Source Documents Date

Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting

Argos Reports Third Quarter 2017 Financial Results and Operational Highlights

Argos Announces Receipt of Milestone Payment from Lummy (Hong Kong) Co. Ltd.

Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017

Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors

Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress

ESMO 2017

Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress

Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir

Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

Tweets